scholarly journals Monogenic Diabetes in Youth With Presumed Type 2 Diabetes: Results From the Progress in Diabetes Genetics in Youth (ProDiGY) Collaboration

Diabetes Care ◽  
2021 ◽  
pp. dc210491
Author(s):  
Jennifer N. Todd ◽  
Jeffrey W. Kleinberger ◽  
Haichen Zhang ◽  
Shylaja Srinivasan ◽  
Sherida E. Tollefsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Monogenic Diabetes ◽  
Diabetes Genetics ◽  
Diabetes In Youth

The First Genome-Wide Association Study (GWAS) for Type 2 Diabetes in Youth from the Progress in Diabetes Genetics in Youth (ProDiGY) Collaboration

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1703-P ◽  
Author(s):  
SHYLAJA SRINIVASAN ◽  
JENNIFER TODD ◽  
LING CHEN ◽  
JASMIN DIVERS ◽  
SAM GIDDING ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Association Study ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
Diabetes Genetics ◽  
Diabetes In Youth

279-OR: Cognition in Young Adults with Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 279-OR
Author(s):  
ALLISON SHAPIRO ◽  
DANA DABELEA ◽  
JEANETTE M. STAFFORD ◽  
RALPH DAGOSTINO ◽  
CATHERINE PIHOKER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Young Adults ◽  
Onset Type ◽  
Youth Study ◽  
Diabetes In Youth

scholarly journals Current Perspectives on Management of Type 2 Diabetes in Youth

Children ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. 37
Author(s):  
Sachi Singhal ◽  
Seema Kumar
Keyword(s):  
Type 2 Diabetes ◽  
Severe Obesity ◽  
Rapid Development ◽  
Adult Onset ◽  
Socioeconomically Disadvantaged ◽  
Lifestyle Modifications ◽  
First Line ◽  
Diabetes In Youth ◽  
First Line Treatment

The prevalence of type 2 diabetes mellitus (T2DM) in children and adolescents is on the rise, and the increase in prevalence of this disorder parallels the modern epidemic of childhood obesity worldwide. T2DM affects primarily post-pubertal adolescents from ethnic/racial minorities and those from socioeconomically disadvantaged backgrounds. Youth with T2DM often have additional cardiovascular risk factors at diagnosis. T2DM in youth is more progressive in comparison to adult onset T2DM and shows lower rates of response to pharmacotherapy and more rapid development of diabetes-related complications. Lifestyle modifications and metformin are recommended as the first-line treatment for youth with T2DM in the absence of significant hyperglycemia. Assessment of pancreatic autoimmunity is recommended in all youth who appear to have T2DM. Pharmacotherapeutic options for youth with T2DM are limited at this time. Liraglutide, a GLP-1 agonist, was recently approved for T2DM in adolescents 10 years of age and older. Several clinical trials are currently underway with youth with T2DM with medications that are approved for T2DM in adults. Bariatric surgery is associated with excellent rates of remission of T2DM in adolescents with severe obesity and should be considered in selected adolescents.

Type 2 Diabetes in Youth in South Asia

2015 ◽  
Vol 15 (2) ◽  
Author(s):  
P. A. Praveen ◽  
S. Ram Kumar ◽  
Nikhil Tandon
Keyword(s):  
Type 2 Diabetes ◽  
South Asia ◽  
Diabetes In Youth

scholarly journals Type 2 Diabetes in Youth

2020 ◽  
Vol 7 ◽  
pp. 2333794X2098134
Author(s):  
Goutham Rao ◽  
Elizabeth T. Jensen
Keyword(s):  
Type 2 Diabetes ◽  
The United States ◽  
Second Line Therapy ◽  
Educational Value ◽  
Line Therapy ◽  
Potential Impact ◽  
Diabetes In Youth ◽  
New Onset

The incidence of type 2 diabetes in children and adolescents in the United States rose at an annual rate of 4.8% between 2002-2003 and 2014-2015. Type 2 diabetes progresses more aggressively to complications than type 1 diabetes. For example, in one large epidemiological study, proliferative retinopathy affected 5.6% and 9.1% of children with type 1 and type 2 diabetes, respectively. Screening begins at age 10 or at onset of puberty, and is recommended among children with a BMI% ≥85 with risk factors such as a family history and belonging to a high risk racial or ethnic or racial group. HbA1C% is preferred for screening as it does not require fasting. As distinguishing between type 1 and type 2 diabetes is not straightforward, all children with new onset disease should undergo autoantibody testing. Results of lifestyle interventions for control of type 2 diabetes have been disappointing, but are still recommended for their educational value and the potential impact upon some participants. There is limited evidence for the benefit of newer mediations. Liraglutide, a GLP-1 agonist, however, has been shown to significantly reduce HbA1C% in one study and is now approved for children. Liraglutide should be considered as second line therapy.

Sign in / Sign up

Export Citation Format

Share Document